BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lipaglyn (Saroglitazar) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lipaglyn (Saroglitazar)\, from ClinicalTr
 ials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05045482-1111@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lipaglyn (Saroglitazar): Phase 1 readout est. (NCT05045482)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 1.\nStudy: Hepatic Impairment W
 ith Cirrhosis Due to Cholestatic Liver Disease\nEstimated primary completi
 on: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /saroglitazar#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT05045482
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06825559-1111@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Lipaglyn (Saroglitazar): Phase 1 readout est. (NCT06825559)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 1.\nStudy: Evaluate PK & Safety
  of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Chole
 static Liver Disease\nEstimated primary completion: 31 December 2026. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/saroglitazar#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06825559
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06427395-1111@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20270418
DTEND;VALUE=DATE:20270419
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT06427395)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Open-Label Extension Study of Saroglitazar Magnesium in Particip
 ants With Primary Biliary Cholangitis\nEstimated primary completion: 18 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitaza
 r#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 427395
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07424677-1111@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07424677)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Study of Saroglitazar Magnesium for PBC Patients With Incomplete
  Response or Intolerant to UDCA Therapy\nEstimated primary completion: Jul
 y 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/saroglitazar#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0742
 4677
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07216235-1111@assetmemo.bio
DTSTAMP:20261121T004939Z
DTSTART;VALUE=DATE:20321130
DTEND;VALUE=DATE:20321201
SUMMARY:Lipaglyn (Saroglitazar): Phase 3 readout est. (NCT07216235)
DESCRIPTION:Lipaglyn (Saroglitazar)\, phase 3\, Primary Biliary Cholangitis
 .\nStudy: Long-Term Study to Evaluate the Safety and Efficacy in Participa
 nts With Primary Biliary Cholangitis of Saroglitazar Magnesium-V on Clinic
 al Outcomes\nEstimated primary completion: November 2032. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/saroglitazar#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07216235
URL:https://assetmemo.bio/drug/saroglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
